Autres langues Vertex Pharmaceuticals Incorporated

Actions

VRTX

US92532F1003

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 04/09/2026			Varia. 5j.	Varia. 1 janv.
546,12 ^USD	-2,12%		+0,29%	+20,46%

02/09	Vertex Pharmaceuticals Incorporated : Evercore ISI reste à l'achat	ZM
01/09	Vertex Pharmaceuticals Incorporated nomme Jonathan Poole au poste de vice-président exécutif, avec effet au 1er janvier 2027	CI

Autres langues

01/09	Vertex Pharmaceuticals Incorporated Announces Chief Financial Officer Changes, Effective January 1, 2027
01/09	Vertex Pharmaceuticals Incorporated Appoints Jonathan Poole as Executive Vice President, Effective January 1, 2027
01/09	Vertex Pharmaceuticals Incorporated completed the acquisition of Crinetics Pharmaceuticals, Inc. from a group of shareholders.
01/09	Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes
01/09	Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition
01/09	Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
26/08	Vertex to Participate in Upcoming September Investor Conferences
12/08	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says
10/08	Vertex Shares Rise as Rival Sionna's Cystic-Fibrosis Trial Fails to Meet Endpoint
10/08	Sionna scraps genetic disorder drug program after trial setback; shares tank
05/08	Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q)
04/08	Tranche Update on Vertex Pharmaceuticals Incorporated's Equity Buyback Plan announced on May 19, 2025.
04/08	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says
04/08	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says
03/08	Vertex Pharmaceuticals Bumps Up Fiscal Year Outlook on Growth of Cystic Fibrosis Drugs
03/08	Vertex: Q2 Earnings Snapshot
03/08	Vertex Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance
03/08	(VRTX) Vertex Pharmaceuticals Now Expects 2026 Revenue Range $13.1B-$13.2B, vs. FactSet Est of $13.06B
03/08	Vertex raises annual revenue forecast on cystic fibrosis drugs strength
03/08	Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Reports Q2 Revenue $3.33B, vs. FactSet Est of $3.23B
03/08	Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Posts Q2 Adjusted EPS $4.73 per Share, vs. FactSet Est of $4.74
03/08	Vertex Reports Second Quarter 2026 Financial Results
03/08	Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for Full Year 2026
03/08	Vertex Pharmaceuticals Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
03/08	Bedrijfskalender van 3 tot 7 augustus 2026